This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Aclidinium inhalation


Dry powder for inhalation containing aclidinium bromide.

Drugs List

  • aclidinium 322microgram dry powder inhaler
  • EKLIRA GENUAIR 322microgram inhalation powder
  • Therapeutic Indications


    Chronic obstructive pulmonary disease



    One inhalation of 322 micrograms aclidinium twice daily.

    Additional Dosage Information

    If a dose is missed the next dose should be taken as soon as possible. However, if it is nearly time for the next dose, the missed dose should not be taken.


    Children under 18 years

    Precautions and Warnings

    Benign prostatic hyperplasia
    Bladder outflow obstruction
    Cardiac arrhythmias
    Glucose-galactose malabsorption syndrome
    Lactose intolerance
    Narrow angle glaucoma
    New York Heart Association class III failure
    New York Heart Association class IV failure
    Unstable angina
    Within 6 months of a myocardial infarction

    Not suitable for acute treatment of bronchospasm
    Advise ability to drive/operate machinery may be affected by side effects
    Ensure patient has a fast acting bronchodilator available
    Contains lactose
    Check patient is using correct inhaler technique
    Prolonged treatment may lead to dental caries
    Discontinue if paradoxical bronchospasm occurs
    Patient should seek medical advice if usual relief is diminished

    Pregnancy and Lactation


    Use aclidinium with caution during pregnancy.

    The manufacturer recommends aclidinium is not used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Some studies in animals have shown foetotoxicity and maternal toxicity only at dose levels much higher than the maximum human exposure to aclidinium. At the time of writing there is limited human data available. Risks are unknown.


    Aclidinium is contraindicated during breastfeeding.

    The manufacturer advises discontinuing breastfeeding or discontinuing aclidinium. Animal studies have shown excretion of small amounts of aclidinium bromide and/or metabolites into milk. It is unknown whether aclidinium and/or its metabolites are excreted in human breast milk.

    Side Effects

    Anaphylactic reaction
    Blurred vision
    Bronchospasm (paradoxical)
    Dry mouth
    Hypersensitivity reactions
    Urinary retention


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2021

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Eklira Genuair 322 micrograms inhalation powder. AstraZeneca UK Ltd. Revised November 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.